Open AccessComparing cure rates for gemtuzumab ozogamicin plus standard chemotherapy vs standard chemotherapy alone in acute myeloid leukemia patients
Author(s) -
Bogdan Muresan,
Carla Mamolo,
Joseph C. Cappelleri,
Ruth Mokgokong,
Athina Palaka,
F Soikkeli,
Bart Heeg
Publication year - 2021
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2020-1287
Subject(s) - gemtuzumab ozogamicin , medicine , myeloid leukemia , chemotherapy , clinical trial , oncology , survival analysis , proportional hazards model , surgery , genetics , stem cell , cd34 , cd33 , biology
Aim: Assess the suitability of standard parametric, piecewise and mixture cure models (MCMs) for modeling long-term survival of acute myeloid leukemia patients achieving remission following treatment with gemtuzumab ozogamicin (GO) + standard chemotherapy (SC) or SC alone. MCMs can model survival data comprising of statistically cured (patients in long-term remission) and uncured patients. Materials & methods: Models were fit to patient-level data corresponding to individual treatment arms. Results: Visual inspection showed that MCMs fit the clinical data best. Survival modeling with MCMs showed that treatment with GO + SC versus SC alone results in higher statistical cure rates for event-free survival (rates: 26–35% vs 21–23%) and overall survival (rates: 48–52% vs 38–44%). Conclusion: MCMs are well suited to modeling long-term survival in acute myeloid leukemia patients. Clinical trial registration: NCT00927498 ( ClinicalTrials.gov )